U.S., May 10 -- ClinicalTrials.gov registry received information related to the study (NCT06964568) titled 'TDLN-sparing RT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC' on May 01.
Brief Summary: The goal of this clinical trial is to learn if tumor draining lymph nodes-sparing radiotherapy (TDLN-sparing RT) followed by immunotherapy as maintenance therapy works to treat locally advanced esophageal squamous cell cancer in adults.
Study Start Date: Feb. 01
Study Type: INTERVENTIONAL
Condition:
Esophageal Carcinoma
Radiotherapy
Immunotherapy
Intervention:
DRUG: PD-1 inhibitor
PD-1 inhibitors will be administered intravenously, a fixed dose of 200 mg, once every 3 weeks for 1 year.
RADIATION: TDLN-sparing rad...